Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 316 participants.
Also called NCT01512979
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 316 participants
- Registry
-
NCT01512979 -
2011-004158-24
-
- Other papers using this trial's data
- Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, India, Israel, Malaysia, Mexico, Philippines, Puerto Rico, Russia, Sri Lanka, Thailand, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01512979. Randomized; double masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2013-04 (actual). Results posted on 2014-05-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- metformin
- Intervention (Drug)
- linagliptin
- Intervention (Drug)
- metformin placebo
- Intervention (Drug)
- metformin placebo
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01512979- Content hash
0f07bae52905a651abf20070c7d186ea513539bf89726f50c4bab15828d06d38